Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02, 7.01, 9.01 · 8-K

CQENS Technologies Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 5, 2026, the Company. distributed a letter to its shareholders of record as of March 5, 2026 providing a review of the company’s recent developments and overview and update on the Company’s plan of operations. A copy of this letter is furnished as Exhibit 99.1 to this report.…

Filed Mar 5, 2026Accepted Mar 5, 2026, 4:44 PM ESTCIK 1479915Accession 0001493152-26-009006
Share

Recent company filings

  1. NT 10-Q filingNov 17, 2026
  2. Other EventsSep 3, 2026
  3. 10-Q filingAug 19, 2026
  4. NT 10-Q filingAug 13, 2026
  5. 10-Q filingMay 14, 2026

Disclosure sections

Items 5.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 5, 2026, the Company. distributed a letter to its shareholders of record as of March 5, 2026 providing a review of the company’s recent developments and overview and update on the Company’s plan of operations. A copy of this letter is furnished as Exhibit 99.1 to this report. Pursuant to General Instruction B.2 of Form 8-K, the information in this Item 7.01 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the company under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 March 5, 2026 To Our Shareholders, The past eight months have seen CQENS make significant progress toward our goal of expanding our valuable, worldwide Intellectual Property (“IP”) portfolio, securing US FDA authorization to launch a modified risk tobacco product in the US, and making significant progress with respect to listing our shares for trading in the public market. In terms of our Intellectual Property (“IP”), during the recent period, we have added to our patent portfolio in the US and in countries in Asia and throughout the European Union. This is in keeping with our strategy of focusing our IP efforts on building a broad and deep “moat” to safeguard the design and the details of our proprietary, patented, and patent pending Heated Tobacco Product (“HTP”), On the US regulatory front, we met with the FDA late in 2025. It is the responsibility of the FDA to thoroughly review our Pre-market Tobacco Authorization (“PMTA”), and to make the determination as to whether we secure the necessary authorization to launch our HTP in the US. In addition, it is important to note that the PMTA is the “gold standard” for international aut…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.